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Clinical trialsAbstract Academic, industry, regulatory leaders and patient advocates in cancer clinical
research met in November 2018 at the Innovation and Biomarkers in Cancer Drug
Development meeting in Brussels to address the existing dichotomy between increasing calls
for personalised oncology approaches based on individual molecular profiles and the need
to make resource and regulatory decisions at the societal level in differing health-care delivery
systems around the globe. Novel clinical trial designs, the utility and limitations of real-world
evidence (RWE) and emerging technologies for profiling patient tumours and tumour-derived
DNA in plasma were discussed. While randomised clinical trials remain the gold standard
approach to defining clinical utility of local and systemic therapeutic interventions, the broad-
er adoption of comprehensive tumour profiling and novel trial designs coupled with RWE may
allow patient and physician autonomy to be appropriately balanced with broader assessments
of safety and overall societal benefit.
ª 2019 Published by Elsevier Ltd.1. Introduction
A dichotomy exists between oncology approaches based
on personalised molecular profiles and resource and
regulatory decisions for societal needs. Broader adop-
tion of tumour profiling, novel trial designs and real-
world evidence (RWE) may facilitate balancing of pa-
tient/physician autonomy with safety concerns and
broader societal benefit.
2. Individual and societal approaches to personalised
medicine in oncology
Recent large-scale collaborative efforts to define the
molecular changes that promote cancer formation and a
deeper understanding of the host immune response have
resulted in a rapidly expanding toolkit of targeted and
immunological therapies. In many cases, these biologi-
cally guided therapies are significantly more effective
and less toxic than traditional cytotoxic agents, often
resulting in durable treatment responses in selected
populations of advanced cancer patients as well as
improved outcomes in resectable tumours (e.g. mela-
noma with immune-oncology and targeted agents).
Historically, the clinical evidence documenting the
effectiveness of newer cancer therapies has been gener-
ated under the guidance of traditional drug approval
pathways, most often through prospective randomised
clinical trials. As many newer targeted therapies are
likely to be effective in smaller subpopulations of pa-
tients, the necessity and relevance of this traditional
drug development paradigm has recently been ques-
tioned. Anecdotal responses in the setting of off-label
use, retrospective analyses of outlier responses or small
cohort studies and even biologic proof-of-concept lab-
oratory data have all been used as justification by on-
cologists and patients to request non-trial access to
newer cancer drugs. These provider and patient de-
mands for access to marketed or investigational drugshave led to increasing tension between point-of-care
oncologists who may wish to pursue individualised
treatment paradigms in the hope of providing benefit to
individuals lacking effective standard treatment options
and national regulatory authorities, such as the United
States Food and Drug Administration (FDA), the Eu-
ropean Medicines Agency (EMA) and the Japanese
Pharmaceuticals and Medical Devices Agency (PMDA),
charged with ensuring that unsafe or ineffective thera-
pies are not approved. Finally, given the high cost of
many novel cancer therapies, Health Technology
Assessment (HTA) bodies advising government payers
and/or private insurers often limit access to non-
standard treatment approaches because of un-
certainties over clinical benefit or as a result of unfav-
ourable cost-benefit analyses.
Despite scientific advances in our understanding of
tumour biology, most regulatory approvals continue to
apply to only a specific therapy, in a particular tumour
type and clinical setting [1]. Although new regulatory
approaches are emerging, their impact so far has been
limited. For example, histology-agnostic clinical trials
have emerged as a tool to assess the broader utility of a
cancer therapeutic in populations defined by a
biomarker rather than tumour type. These histology-
agnostic trials or ‘basket trials’ are a recent innovation
that allow for the testing of newer therapies in patients
with a shared biologic process, for example, a specific
mutation such as BRAF V600E or a mutational signa-
ture coupled with a targeted agent against that process.
Recently, the FDA and PMDA used a tissue-agnostic
clinical trial as the basis for the regulatory approval of
pembrolizumab, a PD-1 targeted antibody, for solid
tumour patients whose cancer are MSI-High or have
DNA mismatch repair deficiency (MSI-H/-dMMR).
EMA, however, has not approved pembrolizumab, and
its perspective differs from that of the FDA. While
pembrolizumab had previously been approved for other
cancer indications, a single-arm tumour agnostic trial
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dMMR patients of any cancer type. Similarly, a small
basket trial led to accelerated FDA approval of laro-
trectinib (LOXO-101) for the treatment of patients with
NTRK-fusion cancers (up to 1% of all solid tumours) of
any primary site in the United States [2]. Larotrectinib
thus represents the first oncology drug to receive a
tumour agnostic indication at the time of initial regu-
latory approval. While these recent successes provide a
roadmap for future histology agnostic drug develop-
ment paradigms, at least in the United States, it remains
unclear whether small basket trials will be sufficient to
influence drug access policies dictated by regulatory
bodies that require more rigorous evidence and HTA
agencies which are charged with assessing the relative
effectiveness and cost-effectiveness of tumour agnostic
drugs as compared with current tumours-specific stan-
dards of care [3]. Notably, both of the aforementioned
tumour agnostic indications were approved, absent a co-
approval for a companion diagnostic test (CDx) in the
United States, which has led to the emergence of
numerous laboratory-derived tests for which the
concordance between methods, e.g. next generation
sequencing (NGS), fluorescence in situ hybridisation
(FISH) and immunohistochemistry (IHC), and the
optimal method for predicting drug response remains
unclear. This has led to significant uncertainty among
treating physicians as to the best methods by which to
screen patients for MSI-H/-dMMR or NTRK fusions.
Thus, in the absence of a single validated test, it is not
clear whether some patients are being harmed by the use
of inaccurate diagnostic tests for which analytical
sensitivity and accuracy are unknown. This is not to
infer that all laboratory developed tests (LDTs) are
inaccurate, but rather that some labs benefit from the
use of standardised closed-system kits. Given these
concerns, the approval of drugs targeting MSI-H/-
dMMR and NTRK were coupled with postmarketing
requirements for the development of companion diag-
nostic devices.
Given the increasingly complex nature of biomarkers
and the need for assays that can rapidly and correctly
identify the optimal patients for individual biologic
therapies, there has been a recognised need for the
development of analytically validated, robust, accurate
and reproducible tests, a need which historically drove
the regulatory recommendation for the development of
drug-specific companion diagnostic tests. Some oncol-
ogists have, however, questioned the need for companies
to develop companion diagnostics for all new cancer
therapies, at least for those that target DNA-based al-
terations such as mutations, gene amplifications or fu-
sions. As multigene NGS assays become increasingly
accurate and cost effective, the necessity of single-gene
companion diagnostics that may increase cost, delay
initiation of therapy and exhaust limited tumour
material is being questioned. In the United States, theFDA has adopted a nimble regulatory framework to
authorise/approve NGS tumour profiling and compan-
ion diagnostic devices, expanding access of analytically
validated tests for patients, while ensuring that
approved CDx markers are safe and effective for iden-
tification of the correct population for the use of the
corresponding therapeutic product.
Adding further complexity, the structures of health-
care systems vastly differ worldwide, each operating
under different socioeconomic constraints and utilising
different reimbursement strategies. In Europe, these
differences have led to variability among member states
with regard to access to newer, expensive anticancer
drugs. In the United States, there is variability according
to the policies of individual private or government
payers. Coverage for off-label use of a drug by private
insurance companies often requires patient-by-patient
petitions. If the petition is not successful, the patient or
the prescribing provider is required to pay the bill thus
resulting in increasing disparities in access to care. From
the societal viewpoint, the challenge will be to balance
access to newer therapies, which have more uncertainties
regarding their benefit-to-risk ratios, and the likelihood
that broader non-trial access to off-label therapies
would result in significant increases in health-care
expenditures.3. Conference consensus: biomarkers should not be
developed exclusively as part of development of an
individual drug
The variable response of cancer patients to tradi-
tional and newer targeted and immune-based cancer
treatments has led to intensive efforts to identify bio-
markers that are predictive of drug sensitivity and/or
resistance. In cases where only a minority of patients
with a particular cancer subtype are predicted to benefit,
CDx have been developed in parallel with newer tar-
geted therapies and used as entry criteria for the defin-
itive, often randomised, clinical trials that have resulted
in regulatory approval. These CDx are then typically
marketed at the same time as drug approval and desig-
nated as a gold standard for determining whether an
individual patient should be treated with a specific
anticancer drug. However, this is a problematic
approach for the rapid and cost-effective development
and use of more predictive biomarkers.
As biomarkers predictive of drug response often
represent the underlying biologic mutations or processes
that drive cancer initiation and progression, routine
testing for these mutational processes may have clinical
utility beyond treatment selection. Predictive bio-
markers may also be prognostic markers (for example
HER2 amplification in breast cancer) or aid in correctly
classifying tumours [4,5]. By refining and confirming
disease diagnosis, tumour molecular profiling may aid in
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dard therapeutic approaches such as surgery, radiation
therapy and the use of cytotoxic chemotherapies. Bio-
markers of drug response can also provide insight into
heritable cancer risk (for example pathogenic germline
mutations in the BRCA1 gene are associated with PARP
inhibitor response and increased heritable risk of
ovarian and breast cancers).
As new sequencing technologies enable simultaneous
and inexpensive analysis of DNA alterations in hun-
dreds of genes or even of the entire exome or genome,
the relevance of single mutation or gene focused tests for
the care of individual cancer patients has been increas-
ingly questioned. In patients with lung cancer, therapies
that selectively inhibit the epidermal growth factor re-
ceptor (EGFR), ALK, ROS1, RET, BRAF, MET,
HER2 and NTRK kinases have shown significant anti-
tumour effects in subsets of patients, whose tumours
harbour drug sensitive alterations in these genes. With
colon cancer, targeting the EGFR pathway has only
been shown to be effective in tumours lacking activating
mutations in the KRAS gene [6]. Tumour mutational
burden has also been shown to be predictive of response
to immune checkpoint blockade or even prognostic in
some but not all tumour types. While multiple CDx
could be performed to determine the status of each of
these predictive biomarkers, such an approach is often
less efficient than the use of a single multigene NGS
assay as a diagnostic test. The latter is often likely to
require less tumour tissue, which could be a critical
factor in patients for whom only limited tumour tissue
was available from a diagnostic fine needle aspirate. It is
thus apparent to most experts that for cancer patients,
single gene diagnostic platforms are unlikely to be the
most cost, time and/or tissue efficient means of deter-
mining which treatment approach is most likely to be
effective. Conversely, NGS-based tests may have a
higher failure rate than quantitative polymerase chain
reactionebased tests, their accuracy for the detection of
gene amplifications, deletions and fusions may be less
than that for gene mutations, and they often have longer
turnaround times than methods such as IHC or FISH,
delays which may be problematic in cancers, where even
a short delay may negatively impact outcomes. These
caveats suggest that without the rigorous clinical vali-
dation provided as part of the development of com-
panion diagnostics, multiplexed DNA sequencing assays
may in some instances fail to identify the correct patient
population for administration of targeted therapies or
lead to patients being inappropriately treated or not
receiving timely access to therapeutic agents. Indeed, a
keystone principle underlying personalised medicine is
that a test, which is both analytically and clinically
validated, should be used to identify the correct popu-
lation. The FDA has allowed for tissue agnostic claims
for MSI-H/-dMMR and for NTRK-fusions with post-
marketing commitments for well-validated companiondiagnostics. However, FDA cannot dictate the com-
panion diagnostic technology that sponsors propose to
support a new therapeutic. Moving from single-marker
tests to tests capable of generating multiple results
such as NGS thus suggest that pharma companies work
closely with multiple diagnostic partners. However,
these issues can be mitigated by the implementation of
properly validated multiplex tests using NGS or other
methods in accredited laboratories participating in
external quality assessment [7].
A second informative example regards deleterious
somatic and germline mutations in the BRCA1 gene.
Pathogenic mutations in this gene have been shown to
be predictive of response to PARP inhibitors in patients
with high-grade serous ovarian cancer and likely other
cancer types. Such mutations are also associated with
increased heritable risk of ovarian, breast, prostate,
pancreas and potentially other cancer types. This asso-
ciation with a heritable risk has made it increasingly
routine to test all newly diagnosed ovarian cancer pa-
tients for germline mutations in BRCA1 and other her-
itable risk genes so as to guide the counseling of family
members concerning their potential cancer risk. It
makes little sense and does not provide value to patients
or the health-care system at large to retest patients
known to harbour pathogenic germline mutations in
BRCA1 using the approved CDx, if they later require
treatment with a PARP inhibitor. Rather, there is a need
to tease out germline and tumour mutations versus
tumour-only mutations when addressing heritable mu-
tations, if the mutation is found in the tumour. In
addition, there is a larger need to harmonise informa-
tion, among the clinical community and test developers,
regarding BRCA mutations.
These examples highlight the need to reengineer the
biomarker development process as it relates to CDx and
LDTs. As of 2018, a CDx approval is based on
demonstration that the test result correlates with the
effect of the agent in a trial population or in a bridging
study that reaches back to the drug trial. If a company
or provider wants approval for a new alternative pre-
dictive biomarker, the concern is they will be required to
perform a similar bridging study for the new biomarker.
Without the flexibility proposed in these draft guide-
lines, the expense of generating clinical utility data
would likely reduce competition, artificially elevate the
cost of diagnostic testing and likely slow innovation by
delaying the adoption of newer technology platforms.
Biomarker development is becoming more frequently
integrated into practice changing randomised phase III
studies. Because it would be unethical to repeat such
phase III trials to test the utility of new biomarkers, the
field is limited in its ability to show that newer, poten-
tially more predictive or cost-efficient biomarkers are
equivalent to the CDx-biomarker integrated into the
initial clinical trial. Certainly, different tests for the same
biomarker could be shown to have analytical
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biomarkers. Here, some have argued that it should be
enough to show that the new diagnostic test is ‘equiva-
lent’ analytically and/or biologically. In regard to DNA-
based testing, there is emerging consensus that accepting
local technical validity should be sufficient for certain
biomarkers. The MyPathway trial [NCT02091141] has
demonstrated this approach for HER2 testing [8]. Such
a demonstration could be coupled with prospective
RWE showing that the use of newer diagnostic plat-
forms is associated with similar clinical benefit as older
diagnostic tests. This applies to DNA-based testing as
well as to other IHC tests, where it has been shown that
laboratory developed tests perform as well as CDx in
certain settings [9], obviating the need for strict use of a
CDx-assay for patient selection in a daily practice
setting, for example when using PDL1-assays.
This approach could address many inefficiencies that
arise from the coupling of companion diagnostics to
individual drug development efforts with although un-
certainty regarding clinical validity and identification of
the correct patient population remains. The develop-
ment of the companion diagnostic is sometimes initiated
much later than the clinical study in which the efficacy
of the drug was demonstrated creating challenges for
industry that is trying to comply with regulatory re-
quirements for the companion diagnostic-assay.
Further, as drug approval is often, but not always,
linked to contemporaneous approval based on the
approval of an analytically and clinically validated
companion diagnostic, drug companies may have little
incentive to show that other potentially less expensive
diagnostic tests could be used for the same purpose. It
should also be noted that the less expensive test might
also be based on an older but not necessarily less sen-
sitive or accurate technology for the intended purpose of
the assay. Lowering the cost of a predictive biomarker
test could also threaten the business model of individual
diagnostic companies but may be of interest to other
industry segments, e.g. other diagnostic providers or
payors. For instance, in MyPathway molecular testing
by various local Clinical Laboratory Improvement
Amendments (CLIA) approved laboratories was
acceptable and showed that patients could be accurately
selected for basket studies using any CLIA NGS-based
assay [8]. Another problem is that there are disincentives
to conduct research that could limit the population of
patients treated once a drug is on the market.
Certainly, it is a missed opportunity not to include
the best active comparator in the clinical development
program because this hinders evaluation of added
therapeutic benefit and the development of a valid cost-
effectiveness model [10,11]. Additionally, it is difficult to
correct for this missed opportunity in the postmarketing
phase, and consequently, precious time is lost for pa-
tients. A better alignment of evidentiary requirements
and decision-making of regulators and HTA/payerscould provide patients with earlier access to evidence-
based innovations.
To improve the efficiency of developing newer agents
or combination therapies in mutational subsets vali-
dated as drug targets, industry stakeholders would also
benefit from registries that longitudinally collect muta-
tion and patient-linked demographic and treatment
response data [12e14]. Here, patient screening is per-
formed outside of therapeutic clinical trials under the
auspices of a protocol for longitudinal collection of
cancer patient data and human biological material
without immediate interventional intent. Informed
consent is obtained with language that allows for future
unspecified use of the collected data and human bio-
logical material, provided the undefined future testing
plan is approved by an ethics committee (without repeat
consent).
It cannot be emphasised enough that biomarkers
incorporated into daily practice should be affordable,
reimbursed, analytically valid and accessible to pathol-
ogists in both academic and community-hospital prac-
tices. There thus needs to be a regulatory pathway for
approval of equivalent diagnostic tests of whatever na-
ture, DNA, protein or even morphology (tumour infil-
trating lymphocytes), addressing the same outcome as
the biomarker used in the trial that led to regulatory
approval, after the formal approval of a companion
diagnostic, so as not to artificially inflate prices and
hinder innovation. However, in the experience of regu-
lators, external quality assurance schemes and diag-
nostic laboratories, performance can vary significantly
between different diagnostic devices, and even markers
on an NGS panel may exhibit variability. This is
currently exemplified for assays that quantitate TMB,
where it is currently unclear how the large variety of
different methods and criteria used to test TMB can be
useable in a clinical trial or even daily practice setting.
So, while the canon of companion diagnostics may be
questioned for purposes of expediency and efficiency,
there is an urgent need to increase, not decrease, the
quality of biomarker testing, especially for emerging
biomarkers of increasing complexity because these are
critical for the selection of the correct patient in the era
of personalised medicine. In the current era of labora-
tory accreditation and given the requirement for quality
control proficiency testing schemes, which in some
countries includes governmental control of performance
of biomarker testing, it is not unreasonable to wonder
whether single gene or mutation companion diagnostics
will continue to have a future role in daily practice given
the robust nature and cost-effectiveness of larger gene
panels. This perspective must, however, be tempered by
the reality that individual lives can be dramatically
affected by a suboptimal biomarker test that may lack
analytical and/or clinical validity. There is an urgent
need to resolve this real conflict between the accelerating
pace of technology development in terms of devices and
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for the safe and effective administration of targeted
therapies. Some might suggest that where possible,
biomarker development should not necessarily be tied to
the development of specific drugs. However, clinical
validation of the biomarker to select the appropriate
drug is a keystone principle that ensures safe and
effective administration of drugs in precision medicine.
This is not to say that biomarkers should not be used in
clinical trials to enrich enrolment for patients considered
likely to respond. NCI-MATCH is a master protocol that
includes signal finding, tumour agnostic studies open to
adults with refractory solid tumours, myeloma and lym-
phoma. Individual arms are open to patients with partic-
ularmutations ormutational profiles, and these arms open
and close independently once they have completed
accrual. Initially, NCI-MATCH required central diag-
nostic testing using an NGS panel for the first 6000 pa-
tients but more recently has allowed treatment assignment
to be based on results from validated reference and aca-
demic laboratories that perform genomic screening assays
such as Foundation One CDx, MSK-IMPACT, etc.
[8,14,15]. NCI-MATCH along with France Genomique
2025, SPECTA and other similar efforts may thus help
facilitate the shift from single biomarker testing to the use
of multiplexed assays that can detect mutations in hun-
dreds of genes as well as more complex molecular signa-
tures. Another example is the drug rediscovery protocol
(DRUP; NCT02925234), a prospective, non-randomised
clinical trial which is looking at the effectiveness of linking
genetic profiles of tumours to approved targeted anti-
cancer drugs. Patients are identified based on a Dutch
whole genome sequencing initiative.4. The need for innovative clinical study designs
Clinical trials of new cancer drugs are historically
focused on defining the efficacy of an individual drug or
combination, yet the HTAs for government health sys-
tems and insurance companies as well as approval
bodies such as FDA and EMA additionally require
patient-centred end-points. It might, therefore, be pru-
dent to have a pragmatic plan approved and imple-
mented after ‘conditional approval’ to reflect patient
centricity in sustainable health-care systems or at least
have these bodies advise on the most appropriate end-
points from their perspectives. Further, it will be
essential to involve HTA and regulatory bodies, as well
as patient advocates, at the clinical trial design and data
collection stages rather than only after a clinical trial has
completed accrual and/or analysis.
Increasingly, oncology clinical trials include imaging
response as a primary or secondary end-point. Imaging
has the ability to capture 3D information and therefore,
quantify intratumoural heterogeneity, a cause of treat-
ment resistance, as well as intrapatient heterogeneity, acause of the phenomenon of oligoresistance. Now that
we are moving towards quantitative imaging, protocols
need to standardise procedures for image acquisition
[16,17]. There is also emerging consensus that it is time
to revisit Response Evaluation Criteria in Solid Tu-
mours criteria and move to a more comprehensive and
automated approach to quantifying in 3D tumour
response [18,19]. There are also new quantitative imag-
ing features emerging such as radiomics features or
functional imaging features [20].
Suboptimal study designs (e.g. end-points, compara-
tors) often result in no or delayed approval. Better trial
designs, e.g. use of the right comparator, end-point,
predictive markers and selection of the most appropriate
patient population are needed, especially as one con-
siders that oncologic therapy is becoming more indi-
vidualised based on biomarkers (antigen expression,
mutations, genotype, etc.).
Here, one can ask, what are acceptable end-points for
HTAs? While decision-makers prefer clinically relevant
end-points when determining drug access, e.g. overall
survival (OS), life-years gained and quality of life, drug
developers and regulators are increasingly relying on
surrogate end-points such as progression-free survival
(PFS), objective response rate (ORR), complete remis-
sion (CR) rate or molecular response. While these latter
end-points can be measured earlier, they have not al-
ways been shown to be associated with traditional end-
points such as OS or supported by clinical benefit.
HTAs also often focus on relative effectiveness, cost-
effectiveness or added value which may be difficult to
extrapolate from trials that relay on surrogate end-
points. Recent examples of this include the use of min-
imal residual disease levels as a surrogate for durable
PFS for patients receiving daratumumab for multiple
myeloma, and the use of ORR, CR and partial response
rates as surrogate end-points for durable long-term PFS
responses for patients receiving treatment with axi-
cabtagene ciloleucel.
The advent of personalised medicine has resulted in
increasing fragmentation of patient populations, and
there is thus a need to access and test large numbers of
patients (even in geographically widely dispersed and
varied regions around the globe) to identify sufficient
numbers of patients to enrol in adequately powered
studies. Furthermore, the smaller the data set, the less
comprehensive the data and the closer we move to-
wards a situation where drugs are judged based upon
their effects in individual patients. Selected academics
may have access to ideal patients and novel drugs, and
while not denying there may be activity, the quality
and the quantity of the effect needs to be assessed in
broader, potentially more diverse, populations by
having a larger and well-defined denominator of
greater patient numbers. In most instances, it is pre-
mature for regulators to base approval decisions on the
outcomes of therapeutic experiments done on few
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perhaps this could become more feasible as RWE
methodologies become more developed. Innovative
clinical trial designs are needed that allow patients in
community settings access to investigational therapies
as part of a trial rather than as off-label use. For
example, the AcSé program in France was designed to
evaluate targeted therapies or immunotherapies in a
subset of patients not enrolled in pivotal trials and to
generate clinical data to support future approvals [21].
The use of a drug in a patient outside of a clinical trial
or in situations when data collection is not required is
often viewed as a lost opportunity to gather data that
may help guide the treatment of future patients or by
HTAs as a guide to how best to allocate limited health-
care resources. In sum, non-trial use of drugs should be
limited by finding ways to allow oncologists who lack
effective alternative treatments to try nonstandard
therapies within a trial setting or, as a minimum, all
non-trial use of drugs in non-standard settings should
be monitored in registries that allow data collection,
sharing, and analyses for a broader community and
society. And, in any case, even limited data should be
collected and reported.
The time taken until innovative cancer drugs are
available is often unsatisfactorily long and varies
considerably among the EU member states as well as
between other regions in the world. In Europe, for
example, oncology drugs are reviewed under a cen-
tralised procedure (EMA). The benefit-to-risk ratio is
the basis for approval and marketing application
authorisation applies to all member states [22]. For a
member state to reimburse drugs, evaluation by an
HTA is often required, whereby consideration is placed
on reimbursement issues and relevance for the health-
care system, i.e. therapeutic added value and cost
effectiveness. HTA agencies vary by country and often
need to consider long-term and societal effects of novel
drugs. Such aspects are often not included in the design
of clinical trials and are often overlooked by regulatory
agencies. However, despite several group efforts, EU
member states, with more than 40 national and/or
regional HTAs, still assess benefits and negotiate drug
prices independently. Indeed, there is considerable
variation in the time between marketing authorisation
by EMA and HTA decisions, and there are also often
differing HTA outcomes for the same drug [23].
Alignment of HTA assessments in Europe is therefore a
worthy goal, and pilot projects are ongoing (e.g.
EUnetHTA is a voluntary collaboration of European
HTA agencies with a focus on harmonisation of HTA
assessment criteria). Moreover, there are several
ongoing projects to align evidentiary requirements
throughout the product lifecycle between the EMA and
EUnetHTA [24]. However, it has to be kept in mind
that efforts to shorten the time for marketing approval
via an accelerated or provisional approval process fornew drugs with outstanding activity that address unmet
medical needs must be balanced with the risk of
harming patients should unanticipated or rare toxicities
become apparent following broader clinical use.
The extent to which harmonisation is even possible
or desirable also needs to be explored. In some coun-
tries, companies that make their investigational prod-
ucts available to patients outside of clinical trials are
allowed to charge a fee, whereas in others, they are not.
Another inconsistency is which entity, patient,
company or health system pays for the screening
necessary to detect actionable biomarkers. Patient re-
quests for products that may help them are further
complicated by off-indication requests, pediatric re-
quests when all data was obtained in adults and re-
quests from countries where regulatory approval, for
whatever reason, was not sought. Physicians who are
willing to seek non-trial access to investigational or
off-label drugs for their patients face many
challenges because different companies may have
different policies, different countries have different
procedures and in some countries, there may be legal
or liability concerns. Furthermore, in all of these set-
tings, it must be determined how data will be collected
from these patients so that their outcomes and poten-
tial adverse events are not lost to history but rather
used to the benefit of future patients.
The need remains to generate effectiveness data sets
relevant for HTA. It is not yet clear who is responsible
for these data nor whose responsibility it is to address
uncertainty in these data sets. Further, how can the data
be made relevant for each individual health-care system
and still be generalisable so that redundant trials are not
required? Programs such as SPECTA, MyPathways,
and NCI-MATCH can help collect the needed
data because industry cannot be expected to be able to
do this alone.
Although challenges remain, all stakeholders need
to come together and overcome differences between
the patient-centric views of clinicians and the society-
centric views of regulatory authorities and payers.
There is a marked need to bridge the gap between
individualised oncology, which does not currently
take into account the resource constraints of
health-care systems and population-based oncology,
which often neglects the needs of rare cancer patients
and increasingly rare molecular subtypes of common
cancers. Small regulatory data sets are less useful to
HTA, and efforts to use RWE to develop therapeutic
guidelines need further methodologic refinement to
be useful for HTA decisions. Countries, payers,
academia and industry should support treatment
optimisation and optimal patient selection at an in-
ternational scale that will not delay patient
access. All stakeholders will need to be pushed to
their limits to bridge the individual-societal oncology
dichotomy.
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